Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study

References

• Haas J S, Kaplan C P, Gerstenberger E P, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Internl Med 2004; 140: 184–188
   PubMed Web of Science ®Google Scholar
• Majumdar S R, Almasi E A, Stafford R S. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004; 292: 1983–1988
   PubMed Web of Science ®Google Scholar
• Hersh A L, Stefanick M L, Stafford R S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47–53
   PubMed Web of Science ®Google Scholar
• Hing E, Brett K M. Changes in US prescribing patterns of menopausal hormone therapy, 2001–2003. Obstet Gynecol 2006; 108: 33–40
   PubMed Web of Science ®Google Scholar
• Wei F, Miglioretti D, Connelly M, et al. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 2005; 35: 106–112
   PubMedGoogle Scholar
• Parazzini F, the Progretto Menopausa Italia Study Group. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997–2003. Menopause 2007; 15: 164–170
   Web of Science ®Google Scholar
• Menon U, Burnell M, Sharma A, et al. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007; 14: 462–467
   PubMed Web of Science ®Google Scholar
• Guay M, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 2007; 16: 17–27
   PubMed Web of Science ®Google Scholar
• Faber A, Bouvy M L, Loskamp L, van de Berg P B, Egberts T CG, de Jong-van den Berg L. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005; 60: 641–647
   PubMed Web of Science ®Google Scholar
• Heitmann C, Greiser E, Dören M. The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 2005; 12: 405–411
   PubMed Web of Science ®Google Scholar
• Clanget C, Hinke V, Lange S, Fricke R, Botko R, Pfeilschifter J. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 2005; 113: 529–533
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004; 11: 589–600
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168–182
   PubMed Web of Science ®Google Scholar
• The IMS Executive Committee. Guidelines for hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004; 7: 8–11
   PubMed Web of Science ®Google Scholar
• Arzneimittelkommission der deutschen Ärzteschaft. Pressemitteilung des Vorsitzenden zum Erscheinen der Therapieempfehlung, Hormontherapie im Klimakterium’ (Press release of the chairman of the German Medical Association upon publication of recommendations regarding “Menopausal hormone therapy in the climacteric period”), Berlin, 23 September 2003
   Google Scholar
• Beckmann M, Braendle W, Brucker C, et al. Konsensus-Empfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause (Consensus recommendations regarding use of postmenopausal hormones in the climacteric period and in the menopause). Frauenarzt 2003; 44: 138–141
   Google Scholar
• Du Y, D˛ren M, Melchert H U, Scheidt-Nave C, Knopf H. Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC Women's Health 2007; 7: 19
   PubMedGoogle Scholar
• Ellert U, Knopf H, Ziese T, Kant H, Riedel R. Der Spandauer Gesundheitstest-Beschreibung der Studie (The Spandau Longitudinal Health Study – description of study). Gesundheitswesen 2003; 65: 102–108
   PubMedGoogle Scholar
• Schwerpunktheft: Bundes-Gesundheitssurvey 1998 – Erfahrungen, Ergebnisse und Perspektiven (German National Health Interview and Examination Survey – experiences, results and perspectives). Gesundheitswesen 1999; 61(Special Issue 2)55–222
   Google Scholar
• Knopf H, Melchert H U. Bundes-Gesundheitssurvey: Arzneimittelgebrauch (German national health survey: drug use). Robert Koch-Institut, Berlin 2003
   Google Scholar
• Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data. Springer, New York 2006
   Google Scholar
• SAS Institute Inc. SAS/STAT 9.1 User's Guide. SAS Institute Inc, Cary, NC 2004
   Google Scholar
• Ettinger B, Grady D, Tosteson A NA, Pressman A, Macer J L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003; 102: 1225–1232
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Tosteson A NA, Pressman A, Macer J L. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003; 102: 1233–1239
   PubMed Web of Science ®Google Scholar
• Du Y, Melchert H U, Schäfer-Korting M. Hormone replacement therapy in Germany: determinants and possible health-related outcomes: results of National Health Surveys from 1984 to 1999. Maturitas 2005; 52: 223–234
   PubMed Web of Science ®Google Scholar
• Ringa V, Varnoux N, Piault S, Breart G. Hormone therapy use among postmenopausal French women before the publication of the Women's Health Initiative Study: duration of use and factors associated with discontinuation. Fertil Steril 2005; 83: 1771–1779
   PubMed Web of Science ®Google Scholar
• Travers C, O'Neill S M, Khoo S K, King R. Hormones down under: hormone therapy use after the Women's Health Initiative. Aust N Z J Obstet Gynaecol 2006; 46: 330–335
   PubMed Web of Science ®Google Scholar
• Buist D SM, Newton K M, Miglioretti D L, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004; 104: 1042–1050
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–323
   PubMed Web of Science ®Google Scholar
• Fletcher S W, Colditz G A. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366–368
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003; 10: 6–12
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Vickers M R, MacLennan A H, Lawton B, et al. Main morbidities recorded in the Women's International Study of long Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 239
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002; 106: 1771–1776
   PubMed Web of Science ®Google Scholar
• Post M S, Christella M, Thomassen L GD, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arteriosclerosis, Thrombosis, Vascular Biol 2003; 23: 1116–1121
   PubMed Web of Science ®Google Scholar
• Wegienka G, Havstad S, Kelsey J. Menopausal hormone therapy in a health maintenance organization before and after Women's Health Initiative hormone trials termination. J Women's Health 2006; 15: 369–378
   PubMed Web of Science ®Google Scholar
• Nedrow A, Miller J, Walker M, Nygren P, Huffman L H, Nelson H D. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006; 166: 1453–1465
   PubMed Web of Science ®Google Scholar
• Krebs E E, Ensrud K E, MacDonald R, Wilt T J. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004; 104: 824–836
   PubMed Web of Science ®Google Scholar
• Leung K Y, Ling M, Tang G WK. Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial. Maturitas 2005; 52: 277–285
   PubMed Web of Science ®Google Scholar
• Brett K M, Madans J H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997; 145: 536–545
   PubMed Web of Science ®Google Scholar
• Morabia A, Costanza M. Recent reversal of trends in hormone therapy use in a European population. Menopause 2006; 13: 111–115
   PubMed Web of Science ®Google Scholar
• Spilsbury K, Semmens J B, Hammond I, Bolck A. Persistent high rates of hysterectomy in Western Australia: a population-based study of 83 000 procedures over 23 years. BJOG 2006; 113: 804–809
   PubMed Web of Science ®Google Scholar
• Greiser E. Gutachten zur Anwendung der postmenopausalen Hormontherapie in Deutschland und Vorschläge zur Senkung der Anwendungshäufigkeit. 2008, Internet communication
   Google Scholar
• Brett A S, Carney P I, McKeown R E. Brief report: attitudes toward hormone therapy after the Women's Health Initiative: a comparison of internists and gynecologists. J Gen Intern Med 2005; 20: 416–418
   PubMed Web of Science ®Google Scholar
• Thunell L, Milsom I, Schmidt J, Mattsson L A. Scientific evidence changes prescribing practice – a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. BJOG 2006; 113: 15–20
   PubMed Web of Science ®Google Scholar
• Biglia N, Ujcic E, Kubatzki F, et al. Personal use of hormone therapy by postmenopausal women doctors and male doctors’ wives in Italy after the publication of WHI trial. Maturitas 2006; 54: 181–192
   PubMed Web of Science ®Google Scholar
• Pedersen A T, Iversen O E, Lokkegaard E, et al. Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstet Gynecol Scand 2007; 86: 1490–1495
   PubMed Web of Science ®Google Scholar
• Jantke A, Bühling K J, Sehouli J, Pfüller B, Hindenburg H-J, Lichtenegger W. Zum Einfluss der WHI-Studie auf die Hormonsubstitution in der Praxis – Ergebnisse eine Umfrage unter FrauenärztInnen in Berlin (The impact of the WHI study on prescribing attitudes regarding hormone replacement therapy: a survey among gynaecologists in Berlin). Geburtsh Frauenheilk 2003; 63: 560–565
   Google Scholar